For patients with DD CKD, reductions from baseline in ferritin levels at Weeks 28–52 and hepcidin levels at Week 24 were significant for patients treated with roxadustat compared with ESA regardless of baseline inflammation levels. Here, HAMP is linked to chronic kidney disease.